Artigos de revistas sobre o tema "STAT inhibitors"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "STAT inhibitors".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Ebersbach, Celina, Alicia-Marie K. Beier, Christian Thomas e Holger H. H. Erb. "Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer". Cancers 13, n.º 19 (28 de setembro de 2021): 4854. http://dx.doi.org/10.3390/cancers13194854.
Texto completo da fonteLee, Hyun-Ku, Gita Singh e Sujay Singh. "STAT reporter cell line systems as a tool for cancer therapeutic target screening." Journal of Immunology 200, n.º 1_Supplement (1 de maio de 2018): 169.8. http://dx.doi.org/10.4049/jimmunol.200.supp.169.8.
Texto completo da fonteJones, Dan, Justin Windham, Brian Stewart, Luis Fayad, Alma Rodriguez e Fredrick B. Hagemeister. "Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors." Blood 114, n.º 22 (20 de novembro de 2009): 968. http://dx.doi.org/10.1182/blood.v114.22.968.968.
Texto completo da fonteStanding, David, Emma Feess, Satvik Kodiyalam, Michael Kuehn, Zachary Hamel, Jaimie Johnson, Sufi Mary Thomas e Shrikant Anant. "The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy". Cancers 15, n.º 9 (26 de abril de 2023): 2485. http://dx.doi.org/10.3390/cancers15092485.
Texto completo da fonteRodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, John Weroha e John Hawse. "Abstract 1129: Interrogating JAK/STAT signaling in ovarian cancer as a potential oncogenic driver and therapeutic target". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 1129. http://dx.doi.org/10.1158/1538-7445.am2022-1129.
Texto completo da fonteZhou, Jianbiao, Chonglei Bi, Lai Fong Poon, Viraj J. Janakakumara, Jiaying Khng, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Davidsen K. Davidsen e Chien-Shing Chen. "Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML." Blood 110, n.º 11 (16 de novembro de 2007): 2367. http://dx.doi.org/10.1182/blood.v110.11.2367.2367.
Texto completo da fonteSuzuki, Asuka, Toshikatsu Hanada, Keiichi Mitsuyama, Takafumi Yoshida, Shintaro Kamizono, Tomoaki Hoshino, Masato Kubo et al. "Cis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation". Journal of Experimental Medicine 193, n.º 4 (12 de fevereiro de 2001): 471–82. http://dx.doi.org/10.1084/jem.193.4.471.
Texto completo da fonteGalli Sanchez, Ana Paula, Tatiane Ester Aidar Fernandes e Gustavo Martelli Palomino. "The JAK-STAT Pathway and the JAK Inhibitors". Journal of Clinical Research in Dermatology 7, n.º 5 (30 de novembro de 2020): 1–6. http://dx.doi.org/10.15226/2378-1726/7/5/001128.
Texto completo da fonteWang, Weiyuan, Melanie Cristina Lopez McDonald, Rajashree Hariprasad, Tiara Hamilton e David A. Frank. "Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation". Cancers 16, n.º 7 (31 de março de 2024): 1387. http://dx.doi.org/10.3390/cancers16071387.
Texto completo da fonteHu, Cheng-Ping, Jun-Tao Feng, Yu-Ling Tang, Jin-Qi Zhu, Min-Juan Lin e Ming-En Yu. "LIF Upregulates Expression of NK-1R in NHBE Cells". Mediators of Inflammation 2006 (2006): 1–8. http://dx.doi.org/10.1155/mi/2006/84829.
Texto completo da fonteTolomeo, Manlio, Maria Meli e Stefania Grimaudo. "STAT5 and STAT5 Inhibitors in Hematological Malignancies". Anti-Cancer Agents in Medicinal Chemistry 19, n.º 17 (24 de janeiro de 2020): 2036–46. http://dx.doi.org/10.2174/1871520619666190906160848.
Texto completo da fonteOrlova, Anna, Christina Wagner, Elvin D. de Araujo, Dávid Bajusz, Heidi A. Neubauer, Marco Herling, Patrick T. Gunning, György M. Keserű e Richard Moriggl. "Direct Targeting Options for STAT3 and STAT5 in Cancer". Cancers 11, n.º 12 (3 de dezembro de 2019): 1930. http://dx.doi.org/10.3390/cancers11121930.
Texto completo da fonteZhou, Jianbiao, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon et al. "Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML". Blood 113, n.º 17 (23 de abril de 2009): 4052–62. http://dx.doi.org/10.1182/blood-2008-05-156422.
Texto completo da fonteHaysen, S., A. L. L. Nielsen, P. Qvist e T. W. Kragstrup. "POS0038 GENOMICS OF JAK-STAT SIGNALING IN VENOUS THROMBOEMBOLISM". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 234.1–234. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2593.
Texto completo da fonteZhang, Xuekang, Jun Zhou, Qian Hu, Zhengren Liu, Qiuhong Chen, Wenxiang Wang, Huaigen Zhang, Qin Zhang e Yuanlu Huang. "The Role of Janus Kinase/Signal Transducer and Activator of Transcription Signalling on Preventing Intestinal Ischemia/Reperfusion Injury with Dexmedetomidine". Journal of Nanoscience and Nanotechnology 20, n.º 5 (1 de maio de 2020): 3295–302. http://dx.doi.org/10.1166/jnn.2020.16416.
Texto completo da fonteMoser, Bernhard, Sophie Edtmayer, Agnieszka Witalisz-Siepracka e Dagmar Stoiber. "The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia". Biomedicines 9, n.º 8 (19 de agosto de 2021): 1051. http://dx.doi.org/10.3390/biomedicines9081051.
Texto completo da fonteBrachet-Botineau, Marie, Marion Polomski, Heidi A. Neubauer, Ludovic Juen, Damien Hédou, Marie-Claude Viaud-Massuard, Gildas Prié e Fabrice Gouilleux. "Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers". Cancers 12, n.º 1 (18 de janeiro de 2020): 240. http://dx.doi.org/10.3390/cancers12010240.
Texto completo da fonteKitanaga, Yukihiro, Emiko Imamura, Yutaka Nakahara, Hidehiko Fukahori, Yasutomo Fujii, Satoshi Kubo, Shingo Nakayamada e Yoshiya Tanaka. "In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors". Rheumatology 59, n.º 8 (25 de novembro de 2019): 1957–68. http://dx.doi.org/10.1093/rheumatology/kez526.
Texto completo da fonteRodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, Scott Kaufmann, Saravut J. Weroha e John Hawse. "Abstract 4862: Investigation of the JAK/STAT signaling pathway in chemotherapy and PARP inhibitor resistant ovarian cancer". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 4862. http://dx.doi.org/10.1158/1538-7445.am2023-4862.
Texto completo da fonteRodman, Esther, Michael Emch, Archit Bajaj, Xiaojia Tang, Xiaonan Hou, Scott Kaufmann, Krishna Kalari, John Weroha e John Hawse. "Abstract B002: Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer". Cancer Research 84, n.º 5_Supplement_2 (4 de março de 2024): B002. http://dx.doi.org/10.1158/1538-7445.ovarian23-b002.
Texto completo da fonteLiang, Zengenni, Zhi-Hang Yuan, Yan Wang, Zhong-Hua Du, Jia-Jing Guo, Ling-Li Xia e Yang Shan. "New Mechanistic Insight into the Protective Effects of Ganoderma lucidum Polysaccharides Against Palmitic Acid-Induced Cell Damage in Porcine Intestinal Epithelial Cell Line IPEC-J2". Natural Product Communications 17, n.º 11 (novembro de 2022): 1934578X2211281. http://dx.doi.org/10.1177/1934578x221128103.
Texto completo da fonteKomyod, Waraporn, Uta-Maria Bauer, Peter C. Heinrich, Serge Haan e Iris Behrmann. "Are STATS Arginine-methylated?" Journal of Biological Chemistry 280, n.º 23 (12 de abril de 2005): 21700–21705. http://dx.doi.org/10.1074/jbc.c400606200.
Texto completo da fonteCallus, Bernard A., e Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, n.º 9 (1 de maio de 1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.
Texto completo da fonteCallus, Bernard A., e Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, n.º 9 (1 de maio de 1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.3182_3182_3192.
Texto completo da fonteKuusanmäki, Heikki, Hanna Rajala, Arjan van Adrichem, Muntasir Mamun Majumder, Emma I. Andersson, Krister Wennerberg, Satu Mustjoki e Caroline A. Heckman. "Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies". Blood 124, n.º 21 (6 de dezembro de 2014): 1771. http://dx.doi.org/10.1182/blood.v124.21.1771.1771.
Texto completo da fonteOzawa, Yukiyasu, Ann H. Williams, Myka Estes, Lubomir Sokol, Richard Jove e Alan F. List. "Regulation of Signal Transducers and Activators of Transcription by Src Family Kinase in AML." Blood 106, n.º 11 (16 de novembro de 2005): 2766. http://dx.doi.org/10.1182/blood.v106.11.2766.2766.
Texto completo da fonteSong, Tammy Linlin, Maarja-Liisa Nairismägi, Yurike Laurensia, Jing-Quan Lim, Jing Tan, Zhi-Mei Li, Wan-Lu Pang et al. "Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma". Blood 132, n.º 11 (13 de setembro de 2018): 1146–58. http://dx.doi.org/10.1182/blood-2018-01-829424.
Texto completo da fonteJang, Sun Hee, e Ji Hyeon Ju. "Janus kinase inhibitors for the treatment of rheumatoid arthritis". Journal of the Korean Medical Association 64, n.º 2 (10 de fevereiro de 2021): 105–8. http://dx.doi.org/10.5124/jkma.2021.64.2.105.
Texto completo da fonteBanes, Amy K., Séan Shaw, John Jenkins, Heather Redd, Farhad Amiri, David M. Pollock e Mario B. Marrero. "Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli". American Journal of Physiology-Renal Physiology 286, n.º 4 (abril de 2004): F653—F659. http://dx.doi.org/10.1152/ajprenal.00163.2003.
Texto completo da fonteThomas, Sally J., Katherine Fisher, Stephen Brown, John A. Snowden, Sarah Danson e Martin Zeidler. "Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling". Blood 124, n.º 21 (6 de dezembro de 2014): 4577. http://dx.doi.org/10.1182/blood.v124.21.4577.4577.
Texto completo da fonteSeverin, Frezzato, Visentin, Martini, Trimarco, Carraro, Tibaldi et al. "In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment". Cancers 11, n.º 12 (4 de dezembro de 2019): 1939. http://dx.doi.org/10.3390/cancers11121939.
Texto completo da fonteLEJEUNE, Diane, Jean-Baptiste DEMOULIN e Jean-Christophe RENAULD. "Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling". Biochemical Journal 353, n.º 1 (18 de dezembro de 2000): 109–16. http://dx.doi.org/10.1042/bj3530109.
Texto completo da fonteMalemud, Charles J. "The role of the JAK/STAT signal pathway in rheumatoid arthritis". Therapeutic Advances in Musculoskeletal Disease 10, n.º 5-6 (19 de maio de 2018): 117–27. http://dx.doi.org/10.1177/1759720x18776224.
Texto completo da fonteHindupur, Sruthi V., Sebastian C. Schmid, Jana Annika Koch, Ahmed Youssef, Eva-Maria Baur, Dongbiao Wang, Thomas Horn et al. "STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy". International Journal of Molecular Sciences 21, n.º 3 (7 de fevereiro de 2020): 1106. http://dx.doi.org/10.3390/ijms21031106.
Texto completo da fonteJeong, Ga Hee, e Ji Hyun Lee. "Dysregulated Hippo Signaling Pathway and YAP Activation in Atopic Dermatitis: Insights from Clinical and Animal Studies". International Journal of Molecular Sciences 24, n.º 24 (10 de dezembro de 2023): 17322. http://dx.doi.org/10.3390/ijms242417322.
Texto completo da fonteKim, Lee, Song, Park, Gadhe, Choi, Lee, Pae, Kim e Ye. "Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy". Journal of Clinical Medicine 8, n.º 11 (2 de novembro de 2019): 1847. http://dx.doi.org/10.3390/jcm8111847.
Texto completo da fonteDemosthenous, Christos, Guangzhen Hu, Thomas E. Witzig e Mamta Gupta. "Loss-of-Function Missense Mutations in Tyrosine Phosphatase PTPN6 Deregulate STAT3 Signaling in Diffuse Large B-Cell Lymphoma". Blood 124, n.º 21 (6 de dezembro de 2014): 707. http://dx.doi.org/10.1182/blood.v124.21.707.707.
Texto completo da fonteKoppikar, Priya, Omar Abdel-Wahab, Cyrus Hedvat, Sachie Marubayashi, Jay Patel, Aviva Goel, Nicole Kucine et al. "Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis". Blood 115, n.º 14 (8 de abril de 2010): 2919–27. http://dx.doi.org/10.1182/blood-2009-04-218842.
Texto completo da fonteCacciapaglia, F., S. Perniola, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, M. Fornaro e F. Iannone. "AB0134 IN-VITRO STUDY ON THE EFFECT OF SELECTIVE Jak-INHIBITORS ON PBMCs STAT3 PHOSPHORYLATION FROM SYSTEMIC SCLEROSIS PATIENTS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 1196.3–1197. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2625.
Texto completo da fonteCacciapaglia, F., V. Venerito, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, N. Lacarpia, M. Fornaro e F. Iannone. "AB0070 INHIBITION OF STAT3 IN PBMCs FROM RHEUMATOID ARTHRITIS PATIENTS: CLUES TO UNDERSTAND SELECTIVITY OF JANUS KINASE INHIBITORS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 1167.2–1168. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1997.
Texto completo da fonteKapuria, Vaibhav, Geoffrey Bartholomeusz, Ling-Yuan Kong, William Bornmann, Zhenghong Peng, Ashutosh Pal, David Maxwell, Moshe Talpaz e Nicholas Donato. "A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling." Blood 110, n.º 11 (16 de novembro de 2007): 1556. http://dx.doi.org/10.1182/blood.v110.11.1556.1556.
Texto completo da fonteMa, Frank Y., Greg M. Anderson, Travis D. Gunn, Vincent Goffin, David R. Grattan e Stephen J. Bunn. "Prolactin Specifically Activates Signal Transducer and Activator of Transcription 5b in Neuroendocrine Dopaminergic Neurons". Endocrinology 146, n.º 12 (1 de dezembro de 2005): 5112–19. http://dx.doi.org/10.1210/en.2005-0770.
Texto completo da fonteAue, Arman, Franziska Szelinski, Sarah Y. Weißenberg, Annika Wiedemann, Thomas Rose, Andreia C. Lino e Thomas Dörner. "Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility". Rheumatology 59, n.º 11 (1 de maio de 2020): 3435–42. http://dx.doi.org/10.1093/rheumatology/keaa187.
Texto completo da fonteNelson, Erik A., Sarah R. Walker, Alicia Kepich, Shariya Terrell, Laurie Gashin e David A. Frank. "Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells." Blood 110, n.º 11 (16 de novembro de 2007): 2953. http://dx.doi.org/10.1182/blood.v110.11.2953.2953.
Texto completo da fonteSimon, Amy R., Satoe Takahashi, Mariano Severgnini, Barry L. Fanburg e Brent H. Cochran. "Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells". American Journal of Physiology-Lung Cellular and Molecular Physiology 282, n.º 6 (1 de junho de 2002): L1296—L1304. http://dx.doi.org/10.1152/ajplung.00315.2001.
Texto completo da fonteVerdeil, Grégory, Toby Lawrence, Anne-Marie Schmitt-Verhulst e Nathalie Auphan-Anezin. "Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy". Cancers 11, n.º 12 (21 de novembro de 2019): 1832. http://dx.doi.org/10.3390/cancers11121832.
Texto completo da fonteTian, Q., H. R. Wang, M. Z. Wang, C. Wang e S. M. Liu. "Lactogenic hormones regulate mammary protein synthesis in bovine mammary epithelial cells via the mTOR and JAK–STAT signal pathways". Animal Production Science 56, n.º 11 (2016): 1803. http://dx.doi.org/10.1071/an14113.
Texto completo da fonteSchwartz, Daniella M., Aran Son, Francoise Meylan, Julio Gomez-Rodriguez, Zenia Kaul, McKella Sylvester, Moses Kitakule et al. "Dynamic chromatin accessibility licenses STAT5- and STAT6-dependent innate-like function of Th9 cells to promote allergic inflammation". Journal of Immunology 210, n.º 1_Supplement (1 de maio de 2023): 67.21. http://dx.doi.org/10.4049/jimmunol.210.supp.67.21.
Texto completo da fonteZong, Hongliang, Tony Taldone, Gail J. Roboz, Gabriela Chiosis e Monica L. Guzman. "A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML". Blood 126, n.º 23 (3 de dezembro de 2015): 2567. http://dx.doi.org/10.1182/blood.v126.23.2567.2567.
Texto completo da fonteFurqan, Muhammad, Akintunde Akinleye, Nikhil Mukhi, Varun Mittal, Yamei Chen e Delong Liu. "STAT inhibitors for cancer therapy". Journal of Hematology & Oncology 6, n.º 1 (2013): 90. http://dx.doi.org/10.1186/1756-8722-6-90.
Texto completo da fonte